A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in node-positive breast cancer patients who have tumors that overexpress HER2.

Trial Profile

A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in node-positive breast cancer patients who have tumors that overexpress HER2.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2020 according to ClinicalTrials.gov record.
    • 11 Dec 2014 Results of intrinsic subtypes, PIK3CA mutation, and the degree of benefit was presented at the 37th Annual San Antonio Breast Cancer Symposium.
    • 28 Aug 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top